NEBULA - multi-omics data platform for airway biology
NEBULA is Diag-Nose's governed, harmonised multi-omics data platform, bringing together molecular, clinical and biological data across studies to make datasets comparable, queryable and reusable for discovery. It uses shared reference controls, per-layer QC, full data provenance and harmonised identifiers to support meaningful comparison and integration of data generated across studies and over time. Partners can contribute cohorts or datasets to this broader biological data environment, enabling cross-study analysis and discovery while retaining appropriate control over their underlying data. NEBULA supports discovery of disease biology, molecular endotypes, biomarkers and drug targets, alongside treatment-response research, clinical trial optimisation, companion-diagnostic development and population level evidence. The MVP is in development, initially spanning asthma, chronic rhinosinusitis and COPD with proteomic data, with architecture designed to expand across diseases, sample types, molecular layers and geographies. We are seeking pharma, biotech, biobank, academic and data-science partners to contribute cohorts, access data or co-develop new applications.
About Diag-Nose.io
Diag-Nose.io is a biotechnology company founded in 2020 that develops precision medicine solutions for respiratory healthcare. The company utilizes a proprietary technology platform called RhinoMAP, which combines nasal liquid biopsies collected via their patented ABEL Microsampler device with advanced proteomics, computational biology, and AI-driven machine learning algorithms. This approach aims to decode the biology of the unified airway—the relationship between the lungs and nasal passages—to provide clinicians with actionable insights into respiratory disease progression and treatment efficacy, particularly regarding anti-Th2 biologics.
The company addresses significant gaps in traditional respiratory care, where treatment decisions are often based on subjective symptoms rather than molecular endotypes, frequently leading to ineffective therapies and prolonged patient distress. By enabling objective, omics-grade biomarker analysis, Diag-Nose.io seeks to reduce side effects, accelerate the development of new lifesaving medicines, and improve treatment adherence for conditions like chronic sinusitis and asthma. Headquartered in Melbourne, Australia, the company has secured FDA listing for its sampling device and completed the global Creative Destruction Lab (CDL) program, underscoring its commitment to bringing rigorous, data-backed precision tools to global clinical and research markets.
delivered to your inbox.